April 24, 2024,  Entinostat Tablets  (trade name: Jingzhuda), a Class 1 innovative drug developed by EOC Pharma, was officially approved by the China NMPA[1]https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240430142236103.html. Entinostat Tablets is indicated for combination with aromatase inhibitors for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative locally advanced or metastatic breast cancer that has recurred or progressed after endocrine therapy. Entinostat is the first innovative drug developed by EOC Pharma. Entinostat works to regulate histone hyper-acetylation and promote transcriptional activation of specific genes by selectively inhibiting class I…

Apr,2024, Shanghai KeChow Pharma’s Category 1 innovative drug Tunlametinib Capsules (Chinese trade name: KELUPING) was approved with conditions by China NMPA. Tunlametinib Capsules is indicate for patients with NRAS-mutated advanced melanoma who have failed PD-1/PD-L1 treatment[1]https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240315082810127.html. Tunlametinib is a selective mitogen-activated protein kinase 1 and kinase 2 (MEK1/2) kinase inhibitor, which plays an antitumor role by inhibiting the activity of MEK1/2 kinase. The marketing of this drug provides new treatment options for patients with advanced NRAS-mutant melanoma who fail anti- PD-1/PD-L1 therapy. It is reported that tunlametinib was well tolerated…

Mar, 2024.4 According to the CDE official website, Hengrui Pharmaceuticals’ clinical trial application for Class 1 new drug SHR-1139 injection has received implicit permission, and the indication is psoriasis.

Feb, 2024. the Category 1 innovative product Ganagliflozin Proline Tablets of Jilin Huisheng Bio-Pharmaceutical Co. Ltd (Huisheng Pharm)was approved for marketing by China NMPA. Ganagliflozin Proline Tablets is a sodium glucose co-transporter 2 (SGLT2) inhibitor that inhibits SGLT2, reduces the re-absorption of filtered glucose, lowers the renal threshold of glucose, and thus increases urine glucose excretion. This is the second independently developed SGLT-2 inhibitor innovative drug to be approved for marketing in China, marking Huisheng’s breakthrough progress in the research and development of innovative drugs in the field of diabetes…

Nov, 2023. Class 1 innovative drug Dimdazenil Capsules from Zhejiang Jingxin Pharmaceutical Co., Ltdis approved for marketing by China NPMA for short term treatment of insomnia disorders.

Nov, 2023. AusperBio（Ausper Biopharma Co.，Ltd. and AusperBio Therapeutics，Inc.）Completed RMB 100 million in Pre-A+ financing by led by InnoPinnacle Fund.

Nov,2023. Jiangxi Ashter Pharmaceutical Co Ltd, branch company of Jemincare, get the drug registration licence for Palbociclib Capsules 75mg, 100mg and 150mg for the treatment of breast cancer. Palbociclib API of Jemincare group get the licence in Nov, 2023 as well.

Nov,2023. Shanghai Argo Biopharmaceutical Co., LTD. (hereinafter referred to as Argo Biopharma)  Completed RMB 300 million in Series A+ financing led by SDIC Investment. 

For occasionally pipetting of special samples, Here are Pipetting Tips for Different Special Types of Sample.

Aponermin for Injection (Brand Name:SHAAITE) of Wuhan HITECK biopharmaceutical Co., Ltd. is approved for marketing by China NMPA, which is used in combination with thalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory Multiple Myeloma after two or more systemic therapies.